J&J wins OK for first in new class of diabetes drugs

Back to TopCommentsE-mailPrintBookmark and Share

Johnson & Johnson, the world’s largest seller of health-care products, won approval for the first in a new family of diabetes drugs, giving them the edge against rivals including Eli Lilly and Co. that are developing similar medicines.

The U.S. Food and Drug Administration cleared the drug, known as canagliflozin, to treat adults with Type 2 diabetes, the agency said Friday in a written statement. It may generate $800 million annually in peak sales, Tony Butler, an analyst at Barclays Plc in New York, said in a telephone interview.

The treatment, to be sold under the name Invokana, expels sugar in the urine after the kidneys filter it from the blood. The FDA has required New Brunswick, N.J.-based J&J to conduct five post-market studies to track possible health risks, including to the heart, bones and pancreas.

“Bringing a new class to market is exciting,” said Kirk Ways, the drug’s development team leader, in a telephone interview. “We need to do better as a nation treating diabetes. Bringing canagliflozin to market will give patients and physicians another option.”

Invokana is part of a family of medicines known as SGLT2 inhibitors intended to have fewer side effects, such as low blood sugar and weight gain, than currently approved diabetes drugs. The company is trying to beat to market similar drugs being developed by Lilly, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Co. and AstraZeneca Plc.

Diabetes is the seventh-leading cause of death in the U.S., according to the Centers for Disease Control and Prevention. The disease, defined by high levels of sugar in the blood, affected almost 26 million people in the U.S. in 2010, or about 8.3 percent of the population, the Atlanta-based CDC said.

While J&J has struggled with recalls and lawsuits over products such as metal hip implants and over-the-counter children’s medicines, the company has gained approval the past two years for new prescription drugs such as the tuberculosis tablet Sirturo, the prostate cancer pill Zytiga and the blood thinner Xarelto. Zytiga generated $961 million in 2012 sales.

For canagliflozin, J&J must study the medicine’s effect on patients’ hearts while the drug is on the market. J&J is working on a cardiovascular study called Canvas that the company plans to complete in 2017, Ways said.

During the first 30 days of treatment, 13 cardiovascular events occurred out of 2,886 patients on canagliflozin in the Canvas trial and one of 1,441 patients taking placebo, according to a January report from FDA staff. The drug raises LDL, or bad cholesterol, which may lead to the heart risk, despite favorable changes in HDL, or good, cholesterol, blood pressure and body weight, staff said.

Invokana probably will be used by doctors as an option after patients fail current therapies, such as Merck & Co’s $4.1 million best-seller Januvia, and cheaper generics including metformin, Butler said.

“What we tried to do with our development program was look across the spectrum,” Ways said. “What we tried to do is arm physicians with the information to prescribe this drug for patients they thought would benefit best.”

Butler’s sales estimate is lower than other diabetes drugs because of the medication’s link to an increased risk of urinary tract infections, particularly in women. Females also experienced an increased risk of vaginal infections.

“I worry its use in women will be somewhat minimal,” Butler said.

Most diabetes treatments on the market stimulate the pancreas to secrete insulin or improve the body’s sensitivity to insulin, a hormone that helps control blood sugar. As the first to work on the kidneys, SGLT2 inhibitors, like the one J&J developed, can be combined with other diabetes medications.

Boehringer, based in Ingelheim, Germany, and Lilly, based in Indianapolis, submitted an application for FDA approval of their SGLT2 inhibitor empagliflozin, the companies said in a March 25 statement. Astellas Pharma Inc. is also working on an SGLT2 inhibitor known as ipragliflozin.

New York-based Bristol-Myers and London-based AstraZeneca are working to address FDA concerns with their product dapagliflozin. The FDA sought more data on dapagliflozin after advisers determined the risks of bladder and breast cancer outweigh the benefits of the medicine.

J&J’s canagliflozin doesn’t show an increased risk of such malignancies, FDA staff said.


Post a comment to this story

We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
You are legally responsible for what you post and your anonymity is not guaranteed.
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
Subscribe to IBJ
  1. These liberals are out of control. They want to drive our economy into the ground and double and triple our electric bills. Sierra Club, stay out of Indy!

  2. These activist liberal judges have gotten out of control. Thankfully we have a sensible supreme court that overturns their absurd rulings!

  3. Maybe they shouldn't be throwing money at the IRL or whatever they call it now. Probably should save that money for actual operations.

  4. For you central Indiana folks that don't know what a good pizza is, Aurelio's will take care of that. There are some good pizza places in central Indiana but nothing like this!!!

  5. I am troubled with this whole string of comments as I am not sure anyone pointed out that many of the "high paying" positions have been eliminated identified by asterisks as of fiscal year 2012. That indicates to me that the hospitals are making responsible yet difficult decisions and eliminating heavy paying positions. To make this more problematic, we have created a society of "entitlement" where individuals believe they should receive free services at no cost to them. I have yet to get a house repair done at no cost nor have I taken my car that is out of warranty for repair for free repair expecting the government to pay for it even though it is the second largest investment one makes in their life besides purchasing a home. Yet, we continue to hear verbal and aggressive abuse from the consumer who expects free services and have to reward them as a result of HCAHPS surveys which we have no influence over as it is 3rd party required by CMS. Peel the onion and get to the root of the problem...you will find that society has created the problem and our current political landscape and not the people who were fortunate to lead healthcare in the right direction before becoming distorted. As a side note, I had a friend sit in an ED in Canada for nearly two days prior to being evaluated and then finally...3 months later got a CT of the head. You pay for what you get...